PriceTargets.com logo

NYSE:DVA - DaVita Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $104.43
  • Forecasted Upside: 12.92 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$92.48 As of 08/12/2022 06:25 PM ET
▲ +0.89 (0.97%)

This chart shows the closing price for DVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DaVita Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DVA

Analyst Price Target is $104.43
▲ +12.92% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for DaVita in the last 3 months. The average price target is $104.43, with a high forecast of $145.00 and a low forecast of $90.00. The average price target represents a 12.92% upside from the last price of $92.48.

This chart shows the closing price for DVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in DaVita. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
2/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
7/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022CowenLower Price Target$95.00N/A
8/4/2022BarclaysLower Price TargetEqual Weight$128.00 ➝ $103.00Low
8/2/2022Deutsche Bank AktiengesellschaftLower Price TargetBuy$150.00 ➝ $97.00Low
6/22/2022Truist FinancialLower Price TargetHold$110.00 ➝ $90.00Low
6/21/2022Bank of AmericaLower Price TargetUnderperform$110.00 ➝ $90.00Low
5/6/2022Truist FinancialLower Price Target$125.00 ➝ $110.00Low
1/5/2022Truist FinancialBoost Price TargetHold ➝ Hold$114.00 ➝ $125.00High
11/17/2021Deutsche Bank AktiengesellschaftLower Price TargetPositive ➝ Buy$164.00 ➝ $150.00Low
10/29/2021Royal Bank of CanadaLower Price TargetSector Perform$113.00 ➝ $111.00High
10/29/2021Deutsche Bank AktiengesellschaftLower Price TargetBuy$207.00 ➝ $164.00High
10/13/2021Truist FinancialLower Price TargetHold$145.00 ➝ $125.00Low
9/9/2021CowenInitiated CoverageMarket Perform$145.00High
8/12/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$135.00 ➝ $146.00Low
8/4/2021William BlairReiterated RatingMarket PerformHigh
7/19/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$150.00 ➝ $207.00Medium
4/1/2021Bank of AmericaReiterated RatingNeutral ➝ Underperform$127.00 ➝ $118.00High
3/26/2021Bank of AmericaDowngradeNeutral ➝ Underperform$127.00 ➝ $118.00Medium
1/13/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$105.00 ➝ $150.00High
1/5/2021Truist FinancialBoost Price Target$100.00 ➝ $130.00N/A
1/5/2021Bank of AmericaDowngradeBuy ➝ Neutral$127.00N/A
9/15/2020Raymond JamesReiterated RatingHoldMedium
7/31/2020SunTrust BanksBoost Price TargetHold$90.00 ➝ $100.00Low
5/6/2020SunTrust BanksBoost Price TargetHold$82.00 ➝ $90.00High
4/20/2020Royal Bank of CanadaReiterated RatingHold$75.00Low
4/13/2020SunTrust BanksLower Price TargetHold$90.00 ➝ $82.00Medium
2/11/2020SunTrust BanksSet Price Target$90.00High
1/24/2020The Goldman Sachs GroupUpgradeNeutral ➝ BuyHigh
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$60.00Low
12/20/2019JPMorgan Chase & Co.Boost Price TargetNeutral$65.00 ➝ $75.00Low
12/18/2019SunTrust BanksBoost Price TargetHold$72.00 ➝ $80.00Medium
11/12/2019Sanford C. BernsteinInitiated CoverageMarket PerformLow
11/7/2019Raymond JamesDowngradeOutperform ➝ Market PerformMedium
11/6/2019SunTrust BanksBoost Price TargetHold$72.00High
10/25/2019Wolfe ResearchDowngradeOutperform ➝ Market Perform$57.00Low
9/11/2019William BlairDowngradeOutperform ➝ Market PerformMedium
9/11/2019SunTrust BanksReiterated RatingPositive ➝ Hold$68.00Medium
8/22/2019UBS GroupLower Price TargetNeutral$61.00 ➝ $60.00Low
7/26/2019Robert W. BairdDowngradeOutperform ➝ Neutral$70.00 ➝ $65.00Medium
6/20/2019William BlairReiterated RatingBuyMedium
5/9/2019Deutsche Bank AktiengesellschaftLower Price TargetBuy$68.00 ➝ $66.00Medium
2/20/2019SunTrust BanksReiterated RatingNeutral ➝ HoldLow
2/15/2019Robert W. BairdLower Price TargetOutperform$90.00 ➝ $70.00Low
1/9/2019Royal Bank of CanadaReiterated RatingHold$65.00Low
1/8/2019UBS GroupUpgradeSell ➝ Neutral$64.00 ➝ $59.00Medium
1/3/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$60.00Medium
12/14/2018BarclaysInitiated CoverageOverweight ➝ Overweight$70.00High
12/2/2018Raymond JamesDowngradeOutperform ➝ Market Perform$63.44Low
11/28/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$70.00High
11/15/2018UBS GroupInitiated CoverageSell ➝ Sell$64.00Medium
11/8/2018Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$70.00 ➝ $78.00High
11/8/2018Raymond JamesDowngradeStrong-Buy ➝ Market PerformN/A
9/13/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralHigh
6/6/2018William BlairReiterated RatingBuyMedium
2/14/2018SunTrust BanksReiterated RatingHold$80.00Medium
2/13/2018Robert W. BairdSet Price TargetBuy$97.00High
1/12/2018Robert W. BairdReiterated RatingBuy$82.00 ➝ $95.00Low
1/11/2018Bank of AmericaReiterated RatingBuy$85.00 ➝ $92.00High
1/4/2018Bank of AmericaUpgradeNeutral ➝ Buy$75.00 ➝ $85.00High
12/21/2017SunTrust BanksSet Price TargetHold$75.00Low
12/12/2017Robert W. BairdUpgradeNeutral ➝ Outperform$63.00 ➝ $82.00Low
12/11/2017CitigroupUpgradeNeutral ➝ Buy$67.71 ➝ $82.00Medium
12/7/2017JPMorgan Chase & Co.Boost Price TargetOutperform ➝ Strong-Buy$4.90 ➝ $84.00Low
12/7/2017SunTrust BanksSet Price TargetSell ➝ Hold$70.00High
12/7/2017Raymond JamesUpgradeOutperform ➝ Strong-Buy$65.00 ➝ $84.00High
12/6/2017KeyCorpReiterated RatingHoldLow
11/13/2017KeyCorpReiterated RatingHoldN/A
11/10/2017Robert W. BairdReiterated RatingHold$63.00N/A
11/8/2017Bank of AmericaLower Price TargetNeutral$75.00 ➝ $66.00N/A
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$64.00 ➝ $60.00N/A
10/23/2017Wolfe ResearchUpgradeMarket Perform ➝ OutperformN/A
10/15/2017SunTrust BanksSet Price TargetHold$57.00N/A
10/10/2017KeyCorpReiterated RatingHoldN/A
10/9/2017JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightN/A
9/6/2017Royal Bank of CanadaReiterated RatingHold$64.00Low
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/14/2022
  • 4 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/13/2022
  • 1 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2022
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2022
  • 4 very positive mentions
  • 23 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
5/14/2022
  • 2 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2022
  • 11 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
7/13/2022
  • 8 very positive mentions
  • 35 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2022

Current Sentiment

  • 8 very positive mentions
  • 35 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

DaVita logo
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Read More

Today's Range

Now: $92.48
Low: $91.43
High: $92.75

50 Day Range

MA: $85.97
Low: $76.05
High: $96.70

52 Week Range

Now: $92.48
Low: $74.97
High: $133.88

Volume

489,012 shs

Average Volume

818,728 shs

Market Capitalization

$8.44 billion

P/E Ratio

11.47

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of DaVita?

The following sell-side analysts have issued reports on DaVita in the last twelve months: Bank of America Co., Barclays PLC, Cowen Inc, Cowen Inc., Deutsche Bank Aktiengesellschaft, Royal Bank of Canada, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for DVA.

What is the current price target for DaVita?

7 Wall Street analysts have set twelve-month price targets for DaVita in the last year. Their average twelve-month price target is $104.43, suggesting a possible upside of 12.9%. Cowen Inc has the highest price target set, predicting DVA will reach $145.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $90.00 for DaVita in the next year.
View the latest price targets for DVA.

What is the current consensus analyst rating for DaVita?

DaVita currently has 1 sell rating, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DVA, but not buy more shares or sell existing shares.
View the latest ratings for DVA.

What other companies compete with DaVita?

Other companies that are similar to DaVita include agilon health, Fresenius Medical Care AG & Co. KGaA, Sotera Health, Progyny and NovoCure. Learn More about companies similar to DaVita.

How do I contact DaVita's investor relations team?

DaVita's physical mailing address is 2000 16TH STREET, DENVER CO, 80202. The company's listed phone number is (720) 631-2100 and its investor relations email address is [email protected] The official website for DaVita is www.davita.com. Learn More about contacing DaVita investor relations.